-
Mashup Score: 6Mayo Clinic's DNA study reveals BRCA1 mutations in 3 sisters, prompts life-changing decisions - Mayo Clinic News Network - 5 month(s) ago
(Sisters left to right: Chris Swatfager, Cindy Larson, Carrie Patnode and Amy Scheid. Photo is courtesy of Chris Swatfager.) Sisters […]
Source: newsnetwork.mayoclinic.orgCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0Validate User - 8 month(s) ago
We are sorry, but we are experiencing unusual traffic at this time. Please help us confirm that you are not a robot and we will take you to your
Source: aacrjournals.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
From the August 1 issue— #BRCA1 Insufficiency Induces a Hypersialylated Acidic #TumorMicroenvironment That Promotes #Metastasis and #Immunotherapy Resistance, by X. Shu et al. https://t.co/VupzHA2KSx @UM_1981 https://t.co/ikrdF1XUGu
-
-
Mashup Score: 1
The Institute of Cancer Research, London, has hailed the ‘life-changing’ decision by NICE to recommend that the targeted drug olaparib can be used for NHS patients with both early-stage breast cancer and prostate cancer.
Source: www.icr.ac.ukCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🧬ICR scientists were the first to demonstrate that cancer cells with mutations in #BRCA1/#BRCA2 were highly susceptible to PARP inhibitors like olaparib - recently recommended for NHS patients with early-stage #BreastCancer and #ProstateCancer 👇 https://t.co/PkrtplErZy #DNADay
-
-
Mashup Score: 1Today - 06/04/2023 - BBC Sounds - 1 year(s) ago
News and current affairs, including Sports Desk, Weather and Thought for the Day.
Source: BBCCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
💊Olaparib has been recommended for both early-stage #BreastCancer and advanced #ProstateCancer caused by faulty #BRCA1 or #BRCA2 genes on the NHS. Professor Andrew Tutt spoke on @BBCr4today about the momentous decision. Listen back from 2:36:40 🎙️ https://t.co/UabS7qzJRD
-
-
Mashup Score: 1
The Institute of Cancer Research, London, has hailed the ‘life-changing’ decision by NICE to recommend that the targeted drug olaparib can be used for NHS patients with both early-stage breast cancer and prostate cancer.
Source: www.icr.ac.ukCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Olaparib - a pioneering PARP inhibitor treatment developed following crucial involvement by ICR scientists - offers people with breast and prostate cancer caused by faulty #BRCA1 or #BRCA2 genes the chance of longer, healthier lives ⬇️ (2/2). https://t.co/PkrtplErZy
-
-
Mashup Score: 8Women in Science: Mary-Claire King - 1 year(s) ago
Mary-Claire King’s life and work serves as an ideal for scientific investigation and using our knowledge to empower communities.
Source: The Jackson LaboratoryCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
For #WomensHistoryMonth, we are revisiting a profile of @uw’s Dr. Mary-Claire King and her pioneering research on the gene #BRCA1 https://t.co/3F79anlRzh #BreastCancer #bcsm https://t.co/e4MGjz3fT2
-
-
Mashup Score: 5The World Tonight - 16/03/2023 - BBC Sounds - 1 year(s) ago
In depth reporting, intelligent analysis and breaking news from a global perspective
Source: BBCCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A variant of the #BRCA1 gene, which is known to increase the risk of #BreastCancer and #OvarianCancer, has been identified in people with Orkney heritage. Hear from the ICR's Prof. @clare__turnbull on @BBCRadio4's The World Tonight (from 22:32). https://t.co/8l5fgzw4Nr
-
-
Mashup Score: 0Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2 - PubMed - 1 year(s) ago
Women diagnosed with breast cancer and known to carry germline PVs in BRCA1, BRCA2, CHEK2, or PALB2 are at substantially increased risk of CBC and may benefit from enhanced surveillance and risk reduction strategies.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
SCI members Ester John, @AllisonKurian and others found that patients who carry a germline #BRCA1, #BRCA2 or #CHEK2 mutation have at least a twofold increased risk of developing cancer in both breasts. https://t.co/z5oNU5mGO3 #ContralateralBreastCancer https://t.co/Xwy1EhpZCm
-
-
Mashup Score: 1Profiling of the genetic features of Chinese patients with gastric cancer with HRD germline mutations in a large-scale retrospective study - 1 year(s) ago
Background Approximately 10% of gastric cancers (GCs) are associated with strong familial clustering and can be attributed to genetic predisposition. Homologous recombination deficiency (HRD) leads to genomic instability and accumulation of genetic variations, playing an important role in the development and progression of cancer. We aimed to delineate the germline mutation characteristics of…
Source: Journal of Medical GeneticsCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Homologous recombination deficiency (HRD) leads plays an important role in the development and progression of gastric #cancer - a large-scale retrospective cohort in China #OpenAccess here: https://t.co/lSmXWkz2qN #ATM #BRIP1 #BRCA1 #BRCA2 #FANCA #PALB2 #Genetics #Genomics https://t.co/K2JxBxoMqg
-
-
Mashup Score: 0Heterozygous BRCA1 and BRCA2 and Mismatch Repair Gene Pathogenic Variants in Children and Adolescents With Cancer - 1 year(s) ago
AbstractBackground. Genetic predisposition is has been identified as a cause of cancer, yet little is known about the role of adult cancer predisposition syndro
Source: OUP AcademicCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Now in @JNCI_Now, new report analyzes if heterozygous pathogenic germline variants in ""adult cancer predisposition syndromes” (#BRCA1 #BRCA2 & MMR genes) are associated with #cancer risk in children and adolescents. #ayacsm Read more: https://t.co/kjpd5yi49V https://t.co/3P53HK4ZMJ
-
RT @MayoCancerCare: Mayo Clinic’s DNA study reveals #BRCA1 mutations in 3 sisters, prompts life-changing decisions: https://t.co/9cJ9fyQ2Iy